Krystal Biotech Inc
KRYS
Get informed when a big investor buys or sells
+ FollowMarket Cap$9.92B
Close$
$302.27
11.6% downside
Current Fair Value
11.6% downsideOvervalued by 11.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $9.92 Billion |
|---|---|
| Enterprise Value | $9.59 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $7.08 |
| Beta | 0.54 |
| Outstanding Shares | 29,529,000 |
Return
| Return on Equity | 17.77% |
|---|---|
| Return on Assets | 16.09% |
| Return on Invested Capital | 14.97% |
Valuation & Multiples
| P/E Ratio | 40.71 |
|---|---|
| PEG | 94.95 |
| Price to Sales | 24.41 |
| Price to Book Ratio | 7.43 |
| Enterprise Value to Revenue | 21.77 |
| Enterprise Value to EBIT | 46.65 |
| Enterprise Value to Net Income | 39 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.07 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 3, 2026
EPS Estimate
$1.70
Average shareholder expectationRevenue Estimate
$120.93 M
Average shareholder expectationNext Earnings Call
Expected Date
November 2, 2026
EPS Estimate
$1.91
Average shareholder expectationRevenue Estimate
$129.65 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.9048▲ 52.46% |
|---|---|
| Total Calls | 232,100▼ 25.15% |
| Total Puts | 210,000▲ 78.12% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 103.48%▲ 6.59% |
|---|---|
| Total Invested | $11.17B▲ 52.52% |
| Investors Holding | 441▲ 60.00% |
ESG Score
No data